A global study led by Paresh Dandona, MD, PhD, found a majority
of patients with Type 1 diabetes who were treated with
dapagliflozin, a Type 2 diabetes medicine, had a significant
decline in their blood sugar levels.
Daniel J. Kosman, PhD, SUNY Distinguished Professor of
biochemistry, has been awarded a five-year, $1.96 million grant
that may lead to advances in understanding the progression of